| Clifford J Schostal, MD | |
|
1615 Delaware St, Longview, WA 98632-2310 | |
| (360) 636-4814 | |
| (360) 414-7965 |
| Full Name | Clifford J Schostal |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 54 Years |
| Location | 1615 Delaware St, Longview, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215939905 | NPI | - | NPPES |
| 146052 | Other | WA | LABOR & IND. |
| 8929331 | Other | WA | CRIME VICTIMS |
| 1099845 | Medicaid | WA | |
| 222844 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | MD00018165 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Peacehealth St John Medical Center | Longview, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Peacehealth | 5890689293 | 182 |
News Archive
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue. Nearly half of all women in the U.S. have dense breast tissue.
The Department of Health and Human Services today released its final medical loss ratio rule. According to an HHS press release, the rule will ensure that health insurance companies spend at least 80 percent of consumers' health insurance premiums on medical care rather than on income, overhead and marketing expenses.
Celera Corporation, a health care company focused on genetics, and Medical Therapies Limited (ASX:MTY), a biotechnology company developing midkine-related diagnostic and therapeutic products, have entered into an exclusive license agreement for the use of MTY's midkine patent portfolio for the development of novel lung cancer diagnostics.
Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.
Despite facing cultural and political pushback, the evidence remains clear: Face masks made a difference in Kansas.
› Verified 4 days ago
| Entity Name | Peacehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720056187 PECOS PAC ID: 5890689293 Enrollment ID: O20040209000272 |
News Archive
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue. Nearly half of all women in the U.S. have dense breast tissue.
The Department of Health and Human Services today released its final medical loss ratio rule. According to an HHS press release, the rule will ensure that health insurance companies spend at least 80 percent of consumers' health insurance premiums on medical care rather than on income, overhead and marketing expenses.
Celera Corporation, a health care company focused on genetics, and Medical Therapies Limited (ASX:MTY), a biotechnology company developing midkine-related diagnostic and therapeutic products, have entered into an exclusive license agreement for the use of MTY's midkine patent portfolio for the development of novel lung cancer diagnostics.
Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.
Despite facing cultural and political pushback, the evidence remains clear: Face masks made a difference in Kansas.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Clifford J Schostal, MD Po Box 249, Longview, WA 98632-7154 Ph: (360) 414-2048 | Clifford J Schostal, MD 1615 Delaware St, Longview, WA 98632-2310 Ph: (360) 636-4814 |
News Archive
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue. Nearly half of all women in the U.S. have dense breast tissue.
The Department of Health and Human Services today released its final medical loss ratio rule. According to an HHS press release, the rule will ensure that health insurance companies spend at least 80 percent of consumers' health insurance premiums on medical care rather than on income, overhead and marketing expenses.
Celera Corporation, a health care company focused on genetics, and Medical Therapies Limited (ASX:MTY), a biotechnology company developing midkine-related diagnostic and therapeutic products, have entered into an exclusive license agreement for the use of MTY's midkine patent portfolio for the development of novel lung cancer diagnostics.
Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.
Despite facing cultural and political pushback, the evidence remains clear: Face masks made a difference in Kansas.
› Verified 4 days ago
Lawrence H. Neville, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1615 Delaware St, Longview, WA 98632 Phone: 360-636-4814 Fax: 360-414-7965 | |
Robert C Axelrod, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 600 Broadway St, Longview, WA 98632 Phone: 360-414-2236 Fax: 360-414-2788 | |
Dr. Yehonatan Shilo, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 600 Broadway St, Longview, WA 98632 Phone: 360-414-2236 Fax: 360-414-2024 | |
Tsz-ming Chow, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1615 Delaware St, Longview, WA 98632 Phone: 360-414-2730 Fax: 360-414-2739 | |
Dr. Laurie Ann Womack, DNP, PMHNP Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1615 Delaware St, Longview, WA 98632 Phone: 360-414-2000 | |
Ms. Rebecca Ann Hopkinson, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1615 Delaware St, Longview, WA 98632 Phone: 360-636-4836 |